119152 | Adenosine A₃ Receptor Antagonist, MRS 1523 - CAS 212329-37-8 - Calbiochem

119152
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Empirical FormulaCAS #
      C₂₃H₂₉NO₃S 212329-37-8

      Pricing & Availability

      Catalogue NumberAvailability Packaging Qty/Pack Price Quantity
      US1119152-5MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      In Stock 
      Discontinued
      Limited Quantities Available
      Availability to be confirmed
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 5 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA pyridine derivative that acts as a highly selective antagonist of A3 receptor with excellent potency in both humans and rodents (Ki = 18.9 nM for human A3R, and 113 nM for rat A3R). Exhibits only a trivial antagonistic activity towards A1 and A2A receptors (Ki = 15.6 µM and 2.05 µM for rat A1R and A2AR, respectively). Abolishes the agonistic effects of Cl-IB-MECA (Cat. No. 119139) on A3R-mediated proliferation of primary human coronary smooth muscle cells. Also, reported to block NECA (Cat. No. 119140)-induced bronchoconstriction in an allergic murine model.
          Catalogue Number119152
          Brand Family Calbiochem®
          Synonyms3-propyl-6-ethyl-5[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate, MRS 1523, MRS-1523
          References
          ReferencesChen, Z., 2012. FASEB J. 26, 1855.
          Chanyshev, B., et al. 2012. Pharmacol Res.65, 338.
          Choi, I., et al. 2011. Am J Pathol. 179, 2042.
          Fan, M., et al. 2003. Am J Physiol Lung Cell Mol Physiol. 284, L1012.
          Li, A. H., et al. 1998. J Med Chem. 41, 3186.
          Jacobson, K. A., et al. 1999. Drug Dev Res. 45, 113.
          Product Information
          CAS number 212329-37-8
          FormClear to light brown oil
          Hill FormulaC₂₃H₂₉NO₃S
          Chemical formulaC₂₃H₂₉NO₃S
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetA₃ Receptor
          Primary Target K<sub>i</sub>18.9 nM
          Purity≥95% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          References

          Reference overview
          Chen, Z., 2012. FASEB J. 26, 1855.
          Chanyshev, B., et al. 2012. Pharmacol Res.65, 338.
          Choi, I., et al. 2011. Am J Pathol. 179, 2042.
          Fan, M., et al. 2003. Am J Physiol Lung Cell Mol Physiol. 284, L1012.
          Li, A. H., et al. 1998. J Med Chem. 41, 3186.
          Jacobson, K. A., et al. 1999. Drug Dev Res. 45, 113.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision19-March-2018 JSW
          Synonyms3-propyl-6-ethyl-5[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate, MRS 1523, MRS-1523
          DescriptionA pyridine derivative that acts as a highly selective antagonist of A3 receptor with excellent potency in both humans and rodents (Ki = 18.9 nM for human A3R, and 113 nM for rat A3R). Exhibits only a trivial antagonistic activity towards A1 and A2A receptors (Ki = 15.6 µM and 2.05 µM for rat A1R and A2AR, respectively). Abolishes the agonistic effects of Cl-IB-MECA (Cat. No. 119139) on A3R-mediated proliferation of primary human coronary smooth muscle cells. Also, reported to block NECA (Cat. No. 119140)-induced bronchoconstriction in an allergic murine model.
          FormClear to light brown oil
          Intert gas (Yes/No) Packaged under inert gas
          CAS number 212329-37-8
          Chemical formulaC₂₃H₂₉NO₃S
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityDMSO (50 mg/ml)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesChen, Z., 2012. FASEB J. 26, 1855.
          Chanyshev, B., et al. 2012. Pharmacol Res.65, 338.
          Choi, I., et al. 2011. Am J Pathol. 179, 2042.
          Fan, M., et al. 2003. Am J Physiol Lung Cell Mol Physiol. 284, L1012.
          Li, A. H., et al. 1998. J Med Chem. 41, 3186.
          Jacobson, K. A., et al. 1999. Drug Dev Res. 45, 113.